	US 12,247,069 B2
	Use of TGF-alpha polypeptide or anti-TGF-alpha antibodies for the treatment of diseases and disorders
George J. Todaro, Seattle, WA (US)
Filed by George J. Todaro, Seattle, WA (US)
Filed on Mar. 1, 2022, as Appl. No. 17/684,305.
Application 17/684,305 is a continuation of application No. 16/693,046, filed on Nov. 22, 2019, granted, now 11,279,753.
Application 16/693,046 is a continuation of application No. 16/534,691, filed on Aug. 7, 2019, abandoned.
Application 16/534,691 is a continuation in part of application No. PCT/US2018/000021, filed on Feb. 16, 2018.
Claims priority of provisional application 62/460,616, filed on Feb. 17, 2017.
Prior Publication US 2022/0267429 A1, Aug. 25, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61P 35/00 (2006.01); C07K 16/22 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/22 (2013.01) [A61K 9/0019 (2013.01); A61P 35/00 (2018.01); A61K 45/06 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01)]

12 Claims

1. A method of reducing tumor size in a subject comprising:

administering to the subject a therapeutically effective amount of an immunotherapeutic treatment comprising an anti-transforming growth factor (TGF) alpha antibody and an anti-programmed cell death protein (PD)-1 and,

optionally, further administering an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), antibody,

wherein the tumor is a TGF-alpha-producing melanoma or lung tumor, and

tumor size fourteen days from administration of the immunotherapeutic treatment is reduced as compared to the size of the tumor after administration of either the anti-TGF-alpha antibody thereof alone or administration of the anti-PD-1 antibody alone, thereby reducing tumor size in the subject.